Method for manufacturing chlorinated compounds
A manufacturing method for a chlorinated compound addresses the limitations of existing treatments by producing intermediates that enhance uric acid excretion, offering a high-yield, cost-effective, and safe solution for hyperuricemia and gout treatment.
Patent Information
- Application Number
- KR1020237001128
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-06-11
- Filing Date
- 2021-06-10
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2041-06-10
AI Technical Summary
Current clinical treatments for hyperuricemia and gout, such as xanthine oxidase inhibitors and urate transporter URAT1 inhibitors, suffer from low efficacy, significant side effects, and high costs, with combination therapies like Lesinurad posing safety risks, particularly renal toxicity at high doses.
A method for manufacturing a chlorinated compound represented by formula (I) using specific reagents and solvents under controlled conditions, including the use of CS2, TEA, and mixed solvents like acetone and methyl tert-butyl ether, to produce intermediates that enhance uric acid excretion and reduce blood uric acid levels safely.
The method provides a high-yield, cost-effective, and easily industrialized process for producing compounds that effectively lower uric acid levels with reduced side effects, facilitating safer long-term treatment of hyperuricemia and gout.
Smart Images

Figure 112023003537984-PCT00069_ABST
Abstract
Description
Technology Field
[0001] The present invention claims the following priority.
[0002] CN202010528778.5, Filing Date: June 11, 2020.
[0003] The present invention relates to a method for manufacturing a chlorinated compound, and specifically to a method for manufacturing a compound represented by formula (I). Background Technology
[0004] In recent years, the incidence of hyperuricemia and gout has been increasing annually due to changes in people's lifestyles. In Europe and the United States, epidemiological studies indicate that gouty arthritis accounts for 1 to 2% of the total population and is the most common type of arthritis among adult men. Bloomberg estimates that the number of gout patients will reach 17.7 million in 2021. In China, surveys show that among the population aged 20 to 74, 25.3% have relatively high blood uric acid levels, and 0.36% suffer from gout. Currently, clinical treatment drugs mainly include: 1) drugs that inhibit uric acid production, such as xanthine oxidase inhibitors like allopurinol and febuxostat; 2) drugs that promote uric acid excretion, such as probenecid and benzbromarone; and 3) anti-inflammatory drugs, such as colchicine. These drugs have specific defects in treatment, low therapeutic efficacy, significant side effects, and high costs, which are major bottlenecks in clinical application. According to reports, 40 to 70 percent of patients did not reach the expected treatment target (<6 mg / dL) after receiving standard course of treatment.
[0005] URAT1 is an important renal anion transporter located at the brush boundary of renal tubular epithelial cells. It specifically transports uric acid from the renal tubules to the epithelial cells and is the primary driving force behind the reabsorption of uric acid in the renal tubules. Therefore, if the urate transporter URAT1 can be significantly inhibited, it can increase the excretion of uric acid from the body, thereby reducing blood uric acid levels and lowering the likelihood of gout attacks.
[0006] In December 2015, the U.S. FDA approved AstraZeneca’s first targeted URAT1 inhibitor, Lesinurad, as shown in the formula below, and also approved its use in combination with a xanthine oxidase inhibitor XOI (e.g., Febuxostat) for the treatment of hyperuricemia and gouty arthritis at a dose of 200 mg / day, but the addition effect of combination therapy is not very significant compared to the administration of a xanthine oxidase inhibitor alone. At the same time, although combination therapy at high doses shows a relatively high addition effect, the 400 mg / day dose of Lesinurad was not approved due to significantly increased toxic side effects observed at high doses (incidence of renal-related side effects, particularly a relatively high incidence of kidney stones). Therefore, the FDA required the addition of a black box warning to the label of resinurad to alert healthcare professionals to the risk of acute renal failure caused by resinurad, noting that this occurs more frequently when not used in combination with XOIs and that the risk of renal failure increases when resinurad is used in doses exceeding the approved range. At the same time, the FDA required AstraZeneca to continue investigating renal and cardiovascular safety even after the market launch of resinurad. Drug safety issues are particularly critical in the case of long-term administration for metabolic diseases. Consequently, the development of safe blood uric acid-lowering agents is a strong demand in this field.
[0007]
[0008] In a published New Drug Registration Notification, AstraZeneca reported in detail the results of validation experiments on liver microsomes and hepatocyte metabolites of the compound lesinurad in vitro in various animal species. According to the data: when lesinurad was metabolized in monkey and human hepatocytes, two major metabolites, M3 and M4, were significantly detected, but M3 and M4 were not detected in dog and rat hepatocytes, as shown in Table-a below.
[0009]
[0010] At the same time, AstraZeneca also reported the major metabolites and metabolic pathways after administering Lesinurad to animals of various species, among which the dihydroxy metabolite M4 was specifically detected in human metabolites.
[0011]
[0012] This was consistent with the human clinical data of lesinurad. Experimental data indicate that M3 and M4 are the most major metabolites found in human clinical trials, as shown in Table-b below.
[0013]
[0014] Through research, it was confirmed that the production pathway of the M4 metabolite is the result of the combined action of cytochrome CYP2C9 and the primate epoxide hydrolase mEH. The mEH metabolic pathway is unique to primate species, which explains why M4 is not observed in rats and dogs.
[0015]
[0016] The present invention provides a method for preparing a compound represented by formula (I), characterized by comprising the following steps:
[0017]
[0018]
[0019] In the above formula,
[0020] n is selected from 0, 1, and 2;
[0021] Reagent A is selected from CS2;
[0022] Base B is TEA, DBU, DIPEA and Selected from;
[0023] Solvent C is selected from a single solvent or a mixed solvent, the single solvent is selected from n-heptane, DMF, acetone, and methyl tert-butyl ether, and the mixed solvent is selected from a mixed solvent of acetone and methyl tert-butyl ether.
[0024] In some embodiments of the present invention, in the manufacturing method,
[0025] Reagent A is selected from CS2;
[0026] Base B is Selected from;
[0027] Solvent C is selected from a single solvent or a mixed solvent, wherein the single solvent is selected from methyl tert-butyl ether, and the mixed solvent is selected from a mixed solvent of acetone and methyl tert-butyl ether.
[0028] In some embodiments of the present invention, in the manufacturing method,
[0029] Reagent A is selected from CS2;
[0030] Base B is Selected from;
[0031] Solvent C is selected from a mixed solvent of acetone and methyl tert-butyl ether.
[0032] In some embodiments of the present invention, in the above manufacturing method, the molar ratio of reagent A to compound 1-2 is 1 to 6:1, the molar ratio of base B to compound 1-2 is 2 to 5:1, and the volume ratio of methyl tert-butyl ether to acetone in the mixed solvent of solvent C is 15 to 25:1.
[0033] In some embodiments of the present invention, in the manufacturing method, in the step of manufacturing compound 1-3A, the temperature range of the reaction system is controlled to 0 to 45°C.
[0034] In some embodiments of the present invention, in the manufacturing method, in the step of manufacturing compound 1-3A, the temperature range of the reaction system is controlled to 30 to 35°C.
[0035] In some embodiments of the present invention, in the manufacturing method, the reaction time is controlled to 16 to 60 hours in the step of manufacturing compound 1-3A.
[0036] In some embodiments of the present invention, the manufacturing method comprises the following steps:
[0037]
[0038] In the above formula,
[0039] Reagent D is selected from hydrazine hydrate;
[0040] Solvent E is selected from EtOH, isopropanol, toluene, MTBE, THF, and DMF;
[0041] Reagent F is selected from DMF-DMA;
[0042] Solvent G is selected from MTBE, EtOAc, n-heptane, THF, isopropanol, and DMF.
[0043] In some embodiments of the present invention, in the manufacturing method,
[0044] Reagent D is selected from hydrazine hydrate;
[0045] Solvent E is selected from EtOH and isopropanol;
[0046] Reagent F is selected from DMF-DMA;
[0047] Solvent G is selected from isopropanol.
[0048] In some embodiments of the present invention, in the manufacturing method, the molar ratio of reagent D to compound 1-3A is 3 to 15:1, and the molar ratio of reagent F to compound 1-4 is 1 to 3:1.
[0049] In some embodiments of the present invention, the manufacturing method comprises the following steps:
[0050]
[0051] In the above formula,
[0052] n is selected from 0, 1, and 2;
[0053] Reagent A, base B, and solvent C are as defined above;
[0054] Reagent D, solvent E, reagent F, and solvent G are as defined above.
[0055] In some embodiments of the present invention, the manufacturing method comprises the following steps:
[0056]
[0057] In the above formula,
[0058] n is selected from 0, 1, and 2;
[0059] Reagent A, base B, and solvent C are as defined above;
[0060] Reagent D, solvent E, reagent F, and solvent G are as defined above;
[0061] The base H is selected from basic compounds;
[0062] Reagent I is selected from NCS;
[0063] Solvent J is selected from EtOAc, DCM, PE, THF, MTBE, and CH3CN;
[0064] Reagent K is Selected from;
[0065] The deoxidizing agent L is selected from K2CO3, NaHCO3, K3PO4, and NaOAc;
[0066] Solvent M is selected from EtOAc, DCM, DMF, THF, and CH3CN;
[0067] Reagent N is selected from NBS and dibromohydantoin;
[0068] Catalyst O is selected from thiocarbonyldiimidazole;
[0069] Solvent P is selected from THF, CH3CN, and EtOAc;
[0070] Reagent Q is selected from bases;
[0071] Solvent R is selected from mixed solvents, and said mixed solvent is selected from a mixed solvent of tetrahydrofuran and water, a mixed solvent of methanol and water, and a mixed solvent of methanol, tetrahydrofuran, and water.
[0072] In some embodiments of the present invention, in the manufacturing method,
[0073] Reagent A, base B, and solvent C are as defined above;
[0074] Reagent D, solvent E, reagent F, and solvent G are as defined above;
[0075] The base H is selected from NaOH;
[0076] Reagent I is selected from NCS;
[0077] Solvent J is selected from EtOAc;
[0078] Reagent K is Selected from;
[0079] Deoxidizing agent L is selected from NaOAc;
[0080] Solvent M is selected from EtOAc;
[0081] Reagent N is selected from NBS;
[0082] Catalyst O is selected from thiocarbonyldiimidazole;
[0083] Solvent P is selected from EtOAc;
[0084] Reagent Q is selected from lithium hydroxide monohydrate, lithium hydroxide, sodium hydroxide, and potassium hydroxide;
[0085] Solvent R is selected from a mixed solvent of tetrahydrofuran and pure water, and the volume ratio of tetrahydrofuran to pure water in the mixed solvent is 0.25 to 4:1.
[0086] The present invention provides a method for preparing a compound represented by formula (I), characterized by comprising the following steps:
[0087]
[0088]
[0089] In the above formula,
[0090] Reagent A is selected from CS2;
[0091] Base B is TEA, DBU, DIPEA and Selected from;
[0092] Solvent C is selected from single solvents and mixed solvents, the single solvent is selected from n-heptane, DMF, acetone, and methyl tert-butyl ether, and the mixed solvent is selected from a mixed solvent of acetone and methyl tert-butyl ether.
[0093] In some embodiments of the present invention, in the manufacturing method,
[0094] Reagent A is selected from CS2;
[0095] Base B is Selected from;
[0096] Solvent C is selected from a single solvent and a mixed solvent, wherein the single solvent is selected from methyl tert-butyl ether, the mixed solvent is selected from a mixed solvent of acetone and methyl tert-butyl ether, and other variables are as defined in the present invention.
[0097] In some embodiments of the present invention, in the manufacturing method,
[0098] Reagent A is selected from CS2;
[0099] Base B is Selected from;
[0100] Solvent C is selected from a mixed solvent of acetone and methyl tert-butyl ether, and other variables are as defined in the present invention.
[0101] In some embodiments of the present invention, in the manufacturing method, the molar ratio of reagent A to compound 1-2 is 1 to 6:1, the molar ratio of base B to compound 1-2 is 2 to 5:1, the volume ratio of methyl tert-butyl ether to acetone in the mixed solvent of solvent C is 15 to 25:1, and other variables are as defined in the present invention.
[0102] In some embodiments of the present invention, in the step of preparing compound 1-3A in the manufacturing method, the temperature range of the reaction system is controlled to 0 to 45°C, and other variables are as defined in the present invention.
[0103] In some embodiments of the present invention, in the step of preparing compound 1-3A in the manufacturing method, the temperature range of the reaction system is controlled to 30 to 35°C, and other variables are as defined in the present invention.
[0104] In some embodiments of the present invention, in the step of preparing compound 1-3A in the manufacturing method, the reaction time is controlled to 16 to 60 hours, and other variables are as defined in the present invention.
[0105] In some embodiments of the present invention, the manufacturing method comprises the following steps:
[0106]
[0107] In the above formula,
[0108] Reagent D is selected from hydrazine hydrate;
[0109] Solvent E is selected from EtOH, isopropanol, toluene, MTBE, THF, and DMF;
[0110] Reagent F is selected from DMF-DMA;
[0111] Solvent G is selected from MTBE, EtOAc, n-heptane, THF, isopropanol, and DMF, and other variables are as defined in the present invention.
[0112] In some embodiments of the present invention, in the manufacturing method,
[0113] Reagent D is selected from hydrazine hydrate;
[0114] Solvent E is selected from EtOH and isopropanol;
[0115] Reagent F is selected from DMF-DMA;
[0116] Solvent G is selected from isopropanol, and other variables are as defined in the present invention.
[0117] In some embodiments of the present invention, in the manufacturing method, the molar ratio of reagent D to compound 1-3A is 3 to 15:1, the molar ratio of reagent F to compound 1-4 is 1 to 3:1, and other variables are as defined in the present invention.
[0118] In some embodiments of the present invention, the manufacturing method comprises the following steps:
[0119]
[0120] In the above formula,
[0121] Reagent A, base B, and solvent C are as defined in the present invention;
[0122] Reagent D, solvent E, reagent F, and solvent G are as defined in the present invention, and other variables are as defined in the present invention.
[0123] In some embodiments of the present invention, the manufacturing method comprises the following steps:
[0124]
[0125] In the above formula,
[0126] Reagent A, base B, and solvent C are as defined in the present invention;
[0127] Reagent D, solvent E, reagent F, and solvent G are as defined in the present invention;
[0128] The base H is selected from basic compounds;
[0129] Reagent I is selected from NCS;
[0130] Solvent J is selected from EtOAc, DCM, PE, THF, MTBE, and CH3CN;
[0131] Reagent K is Selected from;
[0132] The deoxidizing agent L is selected from K2CO3, NaHCO3, K3PO4, and NaOAc;
[0133] Solvent M is selected from EtOAc, DCM, DMF, THF, and CH3CN;
[0134] Reagent N is selected from NBS and dibromohydantoin;
[0135] Catalyst O is selected from thiocarbonyldiimidazole;
[0136] Solvent P is selected from THF, CH3CN, and EtOAc;
[0137] Reagent Q is selected from bases;
[0138] Solvent R is selected from mixed solvents, said mixed solvents are selected from a mixed solvent of tetrahydrofuran and water, a mixed solvent of methanol and water, and a mixed solvent of methanol, tetrahydrofuran, and water, and other variables are as defined in the present invention.
[0139] In some embodiments of the present invention, in the manufacturing method,
[0140] Reagent A, base B, and solvent C are as defined in the present invention;
[0141] Reagent D, solvent E, reagent F, and solvent G are as defined in the present invention;
[0142] The base H is selected from NaOH;
[0143] Reagent I is selected from NCS;
[0144] Solvent J is selected from EtOAc;
[0145] Reagent K is Selected from;
[0146] Deoxidizing agent L is selected from NaOAc;
[0147] Solvent M is selected from EtOAc;
[0148] Reagent N is selected from NBS;
[0149] Catalyst O is selected from thiocarbonyldiimidazole;
[0150] Solvent P is selected from EtOAc;
[0151] Reagent Q is selected from lithium hydroxide monohydrate;
[0152] Solvent R is selected from a mixed solvent of tetrahydrofuran and pure water, and other variables are as defined in the present invention.
[0153] The present invention provides a method for preparing a compound represented by formula (I), characterized by comprising the following steps:
[0154]
[0155]
[0156] In the above formula,
[0157] Reagent A is selected from CS2;
[0158] Base B is Selected from;
[0159] Solvent C is selected from a single solvent or a mixed solvent, the single solvent is selected from n-heptane, DMF, acetone, and methyl tert-butyl ether, and the mixed solvent is selected from a mixed solvent of acetone and methyl tert-butyl ether.
[0160] In some embodiments of the present invention, in the manufacturing method,
[0161] Reagent A is selected from CS2;
[0162] Base B is Selected from;
[0163] Solvent C is selected from a mixed solvent of acetone and methyl tert-butyl ether, and other variables are as defined in the present invention.
[0164] In some embodiments of the present invention, in the manufacturing method, the molar ratio of reagent A to compound 1-2 is 1 to 6:1, the molar ratio of base B to compound 1-2 is 2 to 5:1, the volume ratio of methyl tert-butyl ether to acetone in the mixed solvent of solvent C is 15 to 25:1, and other variables are as defined in the present invention.
[0165] In some embodiments of the present invention, in the step of preparing compound 1-3A in the manufacturing method, the temperature range of the reaction system is controlled to 0 to 45°C, and other variables are as defined in the present invention.
[0166] In some embodiments of the present invention, in the step of preparing compound 1-3A in the manufacturing method, the temperature range of the reaction system is controlled to 30 to 35°C, and other variables are as defined in the present invention.
[0167] In some embodiments of the present invention, in the step of preparing compound 1-3A in the manufacturing method, the reaction time is controlled to 16 to 60 hours, and other variables are as defined in the present invention.
[0168] In some embodiments of the present invention, the manufacturing method comprises the following steps:
[0169]
[0170] In the above formula,
[0171] Reagent D is selected from hydrazine hydrate;
[0172] Solvent E is selected from EtOH, isopropanol, toluene, MTBE, THF, and DMF;
[0173] Reagent F is selected from DMF-DMA;
[0174] Solvent G is selected from MTBE, EtOAc, n-heptane, THF, isopropanol, and DMF, and other variables are as defined in the present invention.
[0175] In some embodiments of the present invention, in the manufacturing method,
[0176] Reagent D is selected from hydrazine hydrate;
[0177] Solvent E is selected from EtOH and isopropanol;
[0178] Reagent F is selected from DMF-DMA;
[0179] Solvent G is selected from isopropanol, and other variables are as defined in the present invention.
[0180] In some embodiments of the present invention, in the manufacturing method, the molar ratio of reagent D to compound 1-3A is 3 to 15:1, the molar ratio of reagent F to compound 1-4 is 1 to 3:1, and other variables are as defined in the present invention.
[0181] In some embodiments of the present invention, the manufacturing method comprises the following steps:
[0182]
[0183] In the above formula,
[0184] Base B is Selected from;
[0185] Reagent A and solvent C are as defined in the present invention;
[0186] Reagent D, solvent E, reagent F, and solvent G are as defined in the present invention, and other variables are as defined in the present invention.
[0187] In some embodiments of the present invention, the manufacturing method comprises the following steps:
[0188]
[0189] In the above formula,
[0190] Base B is Selected from;
[0191] Reagent A and solvent C are as defined in the present invention;
[0192] Reagent D, solvent E, reagent F, and solvent G are as defined in the present invention;
[0193] The base H is selected from basic compounds;
[0194] Reagent I is selected from NCS;
[0195] Solvent J is selected from EtOAc, DCM, PE, THF, MTBE, and CH3CN;
[0196] Reagent K is Selected from;
[0197] The deoxidizing agent L is selected from K2CO3, NaHCO3, K3PO4, and NaOAc;
[0198] Solvent M is selected from EtOAc, DCM, DMF, THF, and CH3CN;
[0199] Reagent N is selected from NBS and dibromohydantoin;
[0200] Catalyst O is selected from thiocarbonyldiimidazole;
[0201] Solvent P is selected from THF, CH3CN, and EtOAc;
[0202] Reagent Q is selected from bases;
[0203] Solvent R is selected from mixed solvents, said mixed solvents are selected from a mixed solvent of tetrahydrofuran and water, a mixed solvent of methanol and water, and a mixed solvent of methanol, tetrahydrofuran, and water, and other variables are as defined in the present invention.
[0204] In some embodiments of the present invention, in the manufacturing method,
[0205] Reagent A, base B, and solvent C are as defined in the present invention;
[0206] Reagent D, solvent E, reagent F, and solvent G are as defined in the present invention;
[0207] The base H is selected from NaOH;
[0208] Reagent I is selected from NCS;
[0209] Solvent J is selected from EtOAc;
[0210] Reagent K is Selected from;
[0211] Deoxidizing agent L is selected from NaOAc;
[0212] Solvent M is selected from EtOAc;
[0213] Reagent N is selected from NBS;
[0214] Catalyst O is selected from thiocarbonyldiimidazole;
[0215] Solvent P is selected from EtOAc;
[0216] Reagent Q is selected from lithium hydroxide monohydrate, lithium hydroxide, sodium hydroxide, and potassium hydroxide;
[0217] Solvent R is selected from a mixed solvent of tetrahydrofuran and pure water, wherein the volume ratio of tetrahydrofuran to pure water in the mixed solvent is 0.25 to 4:1, and other variables are as defined in the present invention.
[0218] The synthesis process of the compound represented by formula (I) and its intermediate provided in the present invention has beneficial effects that overcome disadvantages such as the low cost and ease of obtaining of raw materials, difficulty in separation and purification, and difficulty in industrialization.
[0219] Specifically:
[0220] 1) The raw material for the method of preparing the compound represented by formula (I) of the present invention is a conventional or common reagent, which is readily available on the market and inexpensive, and avoids the use of highly toxic reagents.
[0221] 2) When manufacturing the compound, the reaction conditions are mild and easy to control, post-treatment is simple, and the solid product is precipitated directly, allowing for the production of a product of relatively high purity through simple recrystallization, resulting in a high yield and easy industrialization.
[0222] Therefore, the present invention has high industrial utility and economic value in manufacturing the compound represented by formula (I) and the intermediate thereof. Specific details for implementing the invention
[0223] Definition and explanation
[0224] Unless otherwise specified, the following terms and phrases used in this text have the following meanings. No specific term or phrase shall be considered indeterminate or unclear unless specifically defined otherwise, and shall be understood in its ordinary meaning. Where a product name appears in this text, it indicates the corresponding product or its active ingredient.
[0225] The compounds of the present invention may exist in specific geometric or stereoisomer forms. These compounds anticipated in the present invention include cis and trans isomers, (-)- and (+)- enantiomers, such as mixtures rich in enantiomers or diastereomers, ( R )- and ( S )-enhanced mirror image isomer, diastereomer, ( D )-isomer, ( L )-isomers, and mixtures of racemic mixtures and other mixtures, all of which fall within the scope of the present invention. Other asymmetric carbon atoms may be present in substituents such as alkyl groups. All of these isomers and mixtures thereof fall within the scope of the present invention.
[0226] Unless otherwise specified, the terms “enantiomer” or “optical isomer” refer to stereoisomers that are mirror images of each other.
[0227] Unless otherwise specified, the terms “cis-trans isomer” or “geometric isomer” systems refer to those that cannot rotate freely due to double bonds or single bonds of ring-forming carbon atoms.
[0228] Unless otherwise specified, the term “diastereomer” refers to a stereoisomer in which a molecule has two or more chiral centers and the molecules are in an asymmetric mirror image relationship.
[0229] Unless otherwise specified, “(+)” indicates priority, “(-)” indicates left-handedness, and “(±)” indicates racemicity.
[0230] Unless otherwise specified, wedge-shaped solid line joint ( ) and wedge-shaped dotted line combination( Representing an absolute arrangement of a single three-dimensional center with ), and a linear solid line combination ( ) and linear dotted line combination( ) represents the relative arrangement of the three-dimensional center, and the wavy line( wedge-shaped solid line connection with ) ) or wedge-shaped dotted line connection ( Represents ) or a wavy line ( Straight solid line combination with ) ) or linear dotted line combination ( It represents ).
[0231] Unless otherwise specified, if a compound has a double bond structure such as a carbon-carbon double bond, a carbon-nitrogen double bond, and a nitrogen-nitrogen double bond, and each atom of the double bond is connected to two different substituents (in a double bond involving a nitrogen atom, the lone pair of electrons of the nitrogen atom is considered as one substituent connected thereto), if a wavy line ( If connected by ), the (of the above compound Z )-type isomer, ( EIt represents an isomer of the form or a mixture of two isomers. For example, the following formula (A) indicates that the compound exists in the form of a single isomer of formula (A-1) or formula (A-2) or in the form of a mixture of two isomers of formula (A-1) and formula (A-2); the following formula (B) indicates that the compound exists in the form of a single isomer of formula (B-1) or formula (B-2) or in the form of a mixture of two isomers of formula (B-1) and formula (B-2). The following formula (C) indicates that the compound exists in the form of a single isomer of formula (C-1) or formula (C-2) or in the form of a mixture of two isomers of formula (C-1) and formula (C-2).
[0232] (A) (A-1) (A-2)
[0233] (B) (B-1) (B-2)
[0234] (C) (C-1) (C-2)
[0235] Unless otherwise specified, the term “isomeric excess” or “enantiomer excess” indicates the difference in the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, the isomer or enantiomer excess (ee value) is 80%.
[0236] The compound of the present invention may contain atomic isotopes in non-natural proportions on one or more atoms constituting the compound. For example, tritium ( 3 H), iodine-125( 125 I) or C-14( 14Compounds can be labeled with radioactive isotopes such as C). As another example, deuterated drugs can be formed by replacing hydrogen with deuterium; since the bond composed of deuterium and carbon is stronger than the bond composed of ordinary hydrogen and carbon, deuterated drugs have advantages over non-deuterated drugs, such as reduced side effects, increased drug stability, enhanced drug efficacy, and extended biological half-life. All transformations composed of isotopes of the compounds of the present invention, whether radioactive or not, fall within the scope of the present invention.
[0237] The intermediate compounds of the present invention may be prepared by various synthesis methods known to those skilled in the art, and include specific embodiments exemplified below, embodiments formed by combining the same with other chemical synthesis methods, and equivalent substitution methods known to those skilled in the art, and include but are not limited to the embodiments of the present invention as preferred embodiments.
[0238] The chemical reaction of a specific embodiment of the present invention is completed in a suitable solvent, and said solvent must be suitable for the chemical change of the present invention and the reagents and materials required therefrom. In order to obtain the compound of the present invention, a person skilled in the art may need to modify or select a synthesis step or reaction process based on existing embodiments.
[0239] The present invention will be described in detail through the following examples, but these examples are not intended to limit the invention.
[0240] All solvents used in the present invention are commercially available. The present invention uses the following abbreviations:
[0241]
[0242] Compounds are named using industry-standard naming conventions or ChemDraw® software, and commercially available compounds use the supplier's listing names.
[0243] To better understand the content of the present invention, it is further described in combination with specific embodiments below, but specific embodiments are not intended to limit the content of the present invention.
[0244] Example 1: Preparation of a compound represented by formula (I)
[0245]
[0246] Step 1: Synthesis of Compound 1-2
[0247] Compound 1-1 (1.0 kg, 4.55 mol, 1 eq) was added to 5.0 L of water, the pH was adjusted to approximately 10 with a 2 M aqueous NaOH solution, extracted with 5.0 L of ethyl acetate, the organic phase was dried with anhydrous sodium sulfate, filtered, and the cake was washed with 2.0 L of ethyl acetate. After combining the mother liquors, the mixture was concentrated under reduced pressure to obtain 1-1 in a free state. Under an external temperature of 25 to 30°C, the 1-1 in a free state was dissolved in ethyl acetate (5.0 L), and N - Chlorosuccinimide (668.32 g, 5.01 mol, 1.1 eq) was added in batches, and after the addition was completed, the internal temperature was raised to 40 to 45°C. The obtained reaction solution was continuously stirred for 12 hours. As the reaction proceeded, the internal temperature slowly decreased to 25 to 30°C. The reaction solution was filtered through diatomaceous earth, and the mother liquor was collected. 7.0 L of a 10% aqueous sodium bisulfite solution was added to the mother liquor and stirred for 15 minutes, the liquid was separated, and the organic phase was washed twice with 7.0 L / time with a 10% aqueous sodium bisulfite solution. Next, the obtained organic phase was washed once with water (7.0 L), washed once with a saturated sodium chloride aqueous solution (7.0 L), dried with anhydrous sodium sulfate (1 kg), filtered, and the filtrate concentrated under reduced pressure to obtain compound 1-2 (896.36 g, yield: 90.47%). 1 H NMR (400 MHz, CDCl3) d: 8.41- 8.35 (m, 1H), 7.85 - 7.80 (m, 1H), 7.57 - 7.52 (m, 2H), 7.19 (d, J = 0.8 Hz, 1H), 4.43 (s, 2H), 2.26 - 2.17 (m, 1H), 1.07 - 0.97 (m, 2H), 0.74 - 0.67 (m, 2H); MS m / z: 217.9 [M+H] + .
[0248] Step 2: Synthesis of Compounds 1-3
[0249] Compound 1-2 (650.00 g, 2.98 mol, 1 eq) was dissolved in a mixed solvent of methyl tert-butyl ether and acetone (6.5 L, V:V=95:5) at 25 to 30°C, and then carbon disulfide (1134.49 g, 14.9 mol, 5 eq) and triethylenediamine (1002.79 g, 8.94 mol, 3 eq) were added sequentially while stirring. The resulting reaction solution was stirred at 30 to 35°C for 48 hours. After the reaction was finished, stirring was continued, and the temperature of the reaction solution was programmed down to 0°C (cooling rate controlled at 5°C / hour). The suspension was filtered, and the cake was washed twice with 100 mL / cycle of a mixed solvent of methyl tert-butyl ether and acetone (methyl tert-butyl ether:acetone = 95:5, v:v). The cake was vacuum dried to obtain a pale yellow solid compound 1-3 (1345.68 g, yield: 90.51%). 1 H NMR (400 MHz, DMSO- d 6) δ: 9.86 (br s, 1H), 8.37 - 8.31 (m, 1H), 7.93 - 7.85 (m, 1H), 7.59 - 7.51 (m, 2H), 7.20 (s, 1H), 3.82 (br s, 24H), 2.45 - 2.35 (m, 1H), 1.11 - 1.01 (m, 2H), 0.80 - 0.71 (m, 2H).
[0250] Step 3: Synthesis of Compounds 1-4
[0251] Compound 1-3 (530.0 g, 0.97 mol, 1 eq) and ethanol EtOH (3.5 L) were added to a reaction flask and stirred, and hydrazine hydrate (248.34 g, 4.86 mol, 5 eq) was added dropwise at 20 to 23°C. After the dropwise addition was completed, the resulting mixed solution was stirred for 18 hours at 20 to 23°C, then hydrazine hydrate (12 mL) was added, and stirring continued for 48 hours at 20 to 23°C. The reaction solution was filtered, and the cake was washed twice with ethanol at a rate of 100 mL / time. The cake was collected and dried in a vacuum oven at 35°C to obtain Compound 1-4 (271.82 g, yield: 90.05%). 1 H NMR (400 MHz, DMSO- d 6) δ: 9.22 (br s, 1H), 8.48 - 8.31 (m, 1H), 7.91 - 7.75 (m, 1H), 7.67 - 7.48 (m, 2H), 7.27 (s, 1H), 2.80 (s, 2H), 2.47 - 2.40 (m, 1H), 1.12 - 1.08 (m, 2H), 0.85 - 0.71 (m, 2H); MS m / z: 291.9 [M+H] + .
[0252] Step 4: Synthesis of Compounds 1-5
[0253] 1-4 (260.0 g, 0.89 mol, 1 eq), isopropanol (1.3 L), and N,N-dimethylformamide dimethylacetal (159.26 g, 1.34 mol, 1.5 eq) were sequentially added to a reaction flask, and the resulting mixture solution was stirred at 60°C for 16 hours. The reaction solution was concentrated under reduced pressure to about 500 mL, cooled to room temperature, and the pH of the reaction solution was adjusted to 5 to 6 with a dilute aqueous hydrochloric acid solution (1 M), followed by continuous stirring for 2 hours. The reaction solution was filtered, and the cake was washed with 200 mL of the filtered mother liquor. The cake was collected and vacuum dried to obtain a light gray solid. The solid was stirred and slurried with 2.0 L of n-heptane, stirred at 20 to 25°C for 16 hours, and filtered. The cake was washed twice with n-heptane (200 mL). The cake was collected and dried under reduced pressure to obtain compound 1-5 (210.68 g, yield: 83.35%). 1 H NMR (400MHz, CD3OD) d : 8.58 (d, J = 8.0 Hz, 1H), 8.37 (s, 1H), 7.73 - 7.67 (m, 1H), 7.67 - 7.62 (m, 1H), 7.48 - 7.45 (m, 1H), 7.38 - 7.34 (m, 1H), 2.59 - 2.49 (m, 1H), 1.25 - 1.18 (m, 2H), 0.96 - 0.84 (m, 2H); MS m / z: 301.9 [M+H] + .
[0254] Step 5: Synthesis of Compounds 1-6
[0255] Compound 1-5 (330.02 g) and ethyl acetate (3.3 L) were added sequentially to a 5 L three-necked flask and stirred uniformly. Then, sodium acetate (179.68 g) was added all at once and stirred uniformly. Methyl bromoacetate (200.86 g) was added all at once and stirred uniformly. The resulting reaction solution was stirred and reacted for 16 hours at an external temperature of 60°C. Then, the reaction solution was filtered while hot (external temperature 60°C), the cake was washed twice with ethyl acetate (100 mL), and the filtrates were combined. Four batches (of the same quality) were fed in parallel using the same process, and after the reaction was finished, the filtered ethyl acetate filtrates were combined, and the combining process was performed in the following manner.
[0256] First wash: 14 L of pure water was added to the above ethyl acetate filtrate and stirred vigorously for 20 minutes, then left to stand to separate the layers. After separating the layers, the aqueous phase was discharged, and a small amount of floc layer remained on the ethyl acetate.
[0257] Second washing: 14 L of pure water was added to the ethyl acetate and vigorously stirred for 20 minutes, then left to stand to separate the layers. After separating the layers, the aqueous phase was discharged, and a small amount of floc layer remained on the ethyl acetate.
[0258] Third wash: 14 L of pure water was added to the ethyl acetate phase and vigorously stirred for 20 minutes, then left to stand to separate the layers. After separating the layers, the lower aqueous phase was discharged. The lower organic phase containing a small amount of floc was filtered through diatomaceous earth, combined with the remaining organic phase (total of about 14 L), dried with 5 kg of anhydrous sodium sulfate, filtered, and the filtrate concentrated under reduced pressure to obtain a dark red oil-like substance, which was left to stand and cooled to room temperature to become the crude dark red solid product 1-6 (1640.73 g, yield 87.11%). 1 H NMR (400 MHz, DMSO-d 6 ) δ: 8.94 (s, 1H), 8.58 (d, J =8.0 Hz, 1H), 7.84 - 7.66 (m, 2H), 7.52 (s, 1H), 7.12 (d, J =8.0 Hz, 1H), 4.16 - 4.05 (m, 2H), 3.63 (s, 3H), 2.66 - 2.56 (m, 1H), 1.23 - 1.11 (m, 2H), 1.01 - 0.83 (m, 2H); MS m / z: 374.0 [M+H] + .
[0259] Step 6: Synthesis of Compounds 1-7
[0260] Compound 1-6 (330.05 g) and ethyl acetate (3.3 L) were sequentially added to a 5 L three-necked flask, and the resulting mixed solution was stirred at an external temperature of 40 to 45°C until completely dissolved. While stirring, thiocarbonyldiimidazole (15.73 g) was added and stirred continuously for 10 minutes at an external temperature of 40 to 45°C. While stirring, N-bromosuccinimide (157.10 g) was added in batches, and the resulting reaction solution was stirred continuously for 1 hour at an external temperature of 40 to 45°C. Finally, N-bromosuccinimide (15.74 g) was added and stirred continuously for 15 minutes at an external temperature of 40 to 45°C. The reaction solution was cooled to room temperature, filtered with diatomaceous earth, the cake was washed twice with ethyl acetate (200 mL), and the filtrates were combined. Five batches (of the same quality) were fed in parallel using the same process, and after the reaction was finished, the filtered ethyl acetate filtrates were combined and then combined in the following manner.
[0261] First wash: 17.2 L of pure water was added to the above ethyl acetate filtrate and stirred vigorously for 20 minutes, then left to stand to separate the layers. After separating the layers, the aqueous phase was discharged, and a small amount of floc layer remained on the ethyl acetate.
[0262] Second washing: 17.2 L of a 10% sodium bisulfite solution was added to the ethyl acetate and vigorously stirred for 20 minutes, then left to stand to separate the layers. After separating the layers, the aqueous phase was discharged, and a small amount of floc layer remained on the ethyl acetate.
[0263] Third wash: 17.2 L of a 10% sodium bisulfite solution was added to the ethyl acetate and vigorously stirred for 20 minutes, then left to stand to separate the layers. After separating the layers, the aqueous phase was discharged, and a small amount of floc layer remained on the ethyl acetate.
[0264] Fourth wash: 17.2 L of pure water was added to the ethyl acetate filtrate and stirred vigorously for 20 minutes, then left to stand to separate the layers. After separating the layers, the aqueous phase was discharged, and a small amount of floc layer remained on the ethyl acetate.
[0265] Fifth wash: 17.2 L of pure water was added to the above ethyl acetate filtrate and vigorously stirred for 20 minutes, then left to stand to separate the layers. After separating the layers, the lower aqueous phase was discharged. The lower organic phase containing a small amount of floc was filtered through diatomaceous earth, combined with the remaining organic phase (total of about 17 L), and dried with 8 kg of anhydrous sodium sulfate. The drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure to obtain a crude product (1562.17 g) of dark red solid.
[0266] The above dark red solid was added to methyl tert-butyl ether (5.5 L) and stirred at an external temperature of 80°C until it became transparent. n-heptane (3.5 L) was added to the methyl tert-butyl ether solution and stirred for 16 hours at an external temperature of 60°C, causing a large amount of solid to precipitate from the solution. n-heptane (2.0 L) was added and stirred continuously for 2 hours at an external temperature of 60°C. Then, the temperature of the mixed solution was programmed to an external temperature of 40°C (cooling at 5°C / hour). Stirring was stopped, the mixture was filtered, and the cake was thoroughly washed with n-heptane (1.5 L). The cake was collected and dried under vacuum at 40°C for 2 hours to obtain a pale yellow solid (1107.09 g).
[0267] The above pale yellow solid (1100.01 g) was added to isopropanol (5.5 L), heated to an external temperature of 110°C, and refluxed to obtain a clear solution. The temperature of the isopropanol solution was programmed to an external temperature of 95°C (cooling at 5°C / hour) and stirred continuously at this temperature for 16 hours to precipitate a small amount of off-white solid. The temperature was then programmed to an external temperature of 60°C (cooling at 5°C / hour) and stirred continuously at this temperature for 60 hours to precipitate a large amount of solid. The mixture was filtered while hot, and the cake was thoroughly washed with isopropanol (500 mL). The cake was collected and vacuum dried at 40°C for 16 hours to obtain pale yellow solid 1-7 (962.69 g, yield: 52.27%). 1 H NMR (400MHz, CD3OD) δ: 8.63 (d, J=8.3 Hz, 1H), 7.82 - 7.65 (m, 2H), 7.51 (s, 1H), 7.29 - 7.20 (m, 1H), 4.16 - 3.94 (m, 2H), 3.72 (s, 3H), 2.64 - 2.49 (m, 1H), 1.30 - 1.20 (m, 2H), 0.99 - 0.85 (m, 2H); MS m / z: 453.7 [M+H+2] + .
[0268] Step 7: Synthesis of the compound represented by formula (I)
[0269] Compound 1-7 (330.12 g) was added to a 5 L three-necked flask, and a mixed solution of anhydrous tetrahydrofuran (1650 mL) and pure water (1650 mL) was added and stirred uniformly. Then, lithium hydroxide monohydrate (183.91 g) was added all at once, and the resulting reaction solution was stirred for 2 hours at an external temperature of 30°C. After the reaction was finished, the reaction solution was cooled to room temperature (20°C). Three batches were fed in parallel using the same process, and after combining the reaction solutions, the mixture was processed in the following manner.
[0270] The combined reaction solution was concentrated under reduced pressure (<40°C) to remove tetrahydrofuran, and then the aqueous phase was cooled to 0°C. Under 0°C, an aqueous hydrobromide solution (40%) was added dropwise while stirring until the pH of the mixed solution reached 3, and a large amount of solid precipitated. The mixture was stirred continuously for 16 hours at an external temperature of 20°C, and the pH was re-measured to 3. It was filtered, and the cake was thoroughly washed with pure water (500 mL). The cake was collected and vacuum dried at 40°C for 6 hours to obtain 895.65 g of the crude product of the compound represented by Formula (I). The crude product of the compound represented by Formula (I) (890.12 g) was added to a 10 L three-necked flask, and a mixed solution of ethanol (2225 mL) and pure water (2225 mL) was added and stirred for 48 hours at an external temperature of 40°C. The temperature of the mixture was programmed to an external temperature of 20°C (cooling at 5°C / hour). It was filtered, and the cake was thoroughly washed with a mixed solution of ethanol and pure water (450 mL, V:V=1:1). The cake was collected and dried under vacuum at 40°C for 16 hours to obtain the compound represented by formula (I) (692.16 g, yield: 77.78%). 1 H NMR (400 MHz, DMSO- d 6) δ: 13.02 (s, 1H), 8.61 (d, J =8.4 Hz, 1H), 7.83 - 7.69 (m, 2H), 7.56 (d, J = 8.0 Hz, 1H), 7.19 (d, J =8.4 Hz, 1H), 4.12 - 3.96 (m, 2H), 2.69 - 2.57 (m, 1H), 1.24 - 1.13 (m, 2H), 1.03 - 0.91 (m, 2H); MS m / z: 439.9 [M+H+2] + .
Claims
Claim 1 A method for preparing a compound represented by formula (I) characterized by including the following steps: In the above formula, n is selected from 0, 1, and 2; reagent A is selected from CS2; base B is TEA, DBU, DIPEA, and Selected from; solvent C is a mixed solvent of acetone and methyl tert-butyl ether. Claim 2 In paragraph 1, base B is A manufacturing method selected from. Claim 3 A method of preparation according to claim 1 or 2, wherein the molar ratio of reagent A to compound 1-2 is 1 to 6:1, the molar ratio of base B to compound 1-2 is 2 to 5:1, and the volume ratio of methyl tert-butyl ether to acetone in the mixed solvent of solvent C is 15 to 25:
1. Claim 4 A method of manufacturing according to claim 1 or 2, wherein, in the step of manufacturing compound 1-3A, the temperature range of the reaction system is controlled to 0 to 45℃. Claim 5 A method for manufacturing, wherein, in the step of manufacturing compound 1-3A, the temperature range of the reaction system is controlled to 30 to 35℃. Claim 6 A method of manufacturing according to claim 1 or 2, wherein, in the step of manufacturing compound 1-3A, the reaction time is controlled to 16 to 60 hours. Claim 7 A manufacturing method according to claim 1 or 2, comprising the following steps: In the above formula, reagent D is selected from hydrazine hydrate; solvent E is selected from EtOH, isopropanol, toluene, MTBE, THF, and DMF; reagent F is selected from DMF-DMA; and solvent G is selected from MTBE, EtOAc, n-heptane, THF, isopropanol, and DMF. Claim 8 A method of preparation according to claim 7, wherein solvent E is selected from EtOH and isopropanol; and solvent G is selected from isopropanol. Claim 9 A method of preparation according to claim 8, wherein the molar ratio of reagent D to compound 1-3A is 3 to 15:1 and the molar ratio of reagent F to compound 1-4 is 1 to 3:
1. Claim 10 In claim 8, a manufacturing method comprising the following steps: In the above formula, n is selected from 0, 1, and 2. Claim 11 In claim 10, a manufacturing method comprising the following steps: In the above formula, base H is selected from basic compounds; reagent I is selected from NCS; solvent J is selected from EtOAc, DCM, PE, THF, MTBE, and CH3CN; and reagent K is The deoxidizing agent L is selected from K2CO3, NaHCO3, K3PO4, and NaOAc; the solvent M is selected from EtOAc, DCM, DMF, THF, and CH3CN; the reagent N is selected from NBS and dibromohydantoin; the catalyst O is selected from thiocarbonyldiimidazole; the solvent P is selected from THF, CH3CN, and EtOAc; the reagent Q is selected from a base; and the solvent R is selected from a mixed solvent, wherein the mixed solvent is selected from a mixed solvent of tetrahydrofuran and water, a mixed solvent of methanol and water, and a mixed solvent of methanol, tetrahydrofuran, and water. Claim 12 A method for manufacturing according to claim 11, wherein base H is selected from NaOH; solvent J is selected from EtOAc; deoxidizing reagent L is selected from NaOAc; solvent M is selected from EtOAc; reagent N is selected from NBS; solvent P is selected from EtOAc; reagent Q is selected from lithium hydroxide monohydrate, lithium hydroxide, sodium hydroxide, and potassium hydroxide; and solvent R is selected from a mixed solvent of tetrahydrofuran and pure water, wherein the volume ratio of tetrahydrofuran to pure water in the mixed solvent is 0.25 to 4:
1. Claim 13 delete
Citation Information
Patent Citations
Preparation method of gout curative medicine Lesinurad and midbody of Lesinurad
CN103524440A
A method for synthesizing 4-(4-cyclopropylnaphthalen-1-yl)-1H-1,2,4-triazole-5(4H)-thione
CN104529848A
Halogenated Compounds and Their Axial Chirality Isomers
JP2019518060A
